Harvard researchers personalised cancer vaccine, WDVAX, shows promise in advanced melanoma. Tested in 21 patients, it proved safe and activated immune cells, including T-cells, to target tumours. The Phase I trial confirms feasibility for individualised treatment. Future studies will explore combining WDVAX with immunotherapy for enhanced long-term cancer control.